Bortezomib

Proteasome inhibitor preventing premature CFTR breakdown

Phase of research

FDA-/EMA-approved for Other Purpose

How it helps

Restore CFTR Function

General information

Bortezomib is an anti-cancer medication used to treat multiple myeloma and mantle cell lymphoma. It was approved in the USA in 2003 for medical use and is sold under the name Velcade®. In relation to cystic fibrosis, our AIM tool found the data that bortezomib can help rescue the misfolded F508del-CFTR by inhibiting its degradation. 

Bortezomib on PubChem
Bortezomib on DrugBank
Bortezomib on Wikipedia

Synonyms

PS341

Marketed as

Dietary sources

N/A

Structure image not available

C19H25BN4O4

Drug-Mutation Relation

Treats

Mutation Number of sources Average impact factor
F508del
2 5.63
Link Tested on Impact factor Notes
Rescue of Murine F508del CFTR Activity in Native Intestine by Low Temperature and Proteasome Inhibitors murine cell cultures 3.73
High-content Functional Screen to Identify Proteins that Correct F508del-CFTR Function*S⃞ human cell cultures 7.52

Does not treat

Mutation Number of sources Average impact factor